Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Heart Test Laboratories, Inc. ( (HSCS) ) has shared an announcement.
On January 16, 2025, Heart Test Laboratories, Inc. granted stock options to key executive officers and non-employee directors. The company’s Compensation Committee awarded options to executives, including Andrew Simpson, Mark Hilz, and Danielle Watson, with a vesting schedule over three years. Non-employee directors also received options with a different vesting timeline. These stock options form part of the company’s 2023 Equity Incentive Plan and may accelerate upon achieving regulatory milestones for their products.
More about Heart Test Laboratories, Inc.
YTD Price Performance: -7.22%
Average Trading Volume: 37,640
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.4M
For detailed information about HSCS stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue